Evidence map›Paper›PMID 39385270›Full record

ArticleClinical diabetes and endocrinology2024

Application of a validated prognostic plasma protein biomarker test for renal decline in type 2 diabetes to type 1 diabetes: the Fremantle Diabetes Study Phase II.

Timothy M E Davis, Wendy A Davis, Scott D Bringans, James K C Lui, Tasha S C Lumbantobing, Kirsten E Peters, Richard J Lipscombe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical diabetes and endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Timothy M E DavisMedical School, University of Western Australia, Fremantle Hospital, PO Box 480, WA, 6959, Fremantle, Australia. tim.davis@uwa.edu.au.ORCID http://orcid.org/0000-0003-0749-7411
Wendy A DavisMedical School, University of Western Australia, Fremantle Hospital, PO Box 480, WA, 6959, Fremantle, Australia.
Scott D BringansProteomics International, Nedlands, WA, Australia.
James K C LuiProteomics International, Nedlands, WA, Australia.
Tasha S C LumbantobingProteomics International, Nedlands, WA, Australia.
Kirsten E PetersProteomics International, Nedlands, WA, Australia.
Richard J LipscombeProteomics International, Nedlands, WA, Australia.

Funding

National Health and Medical Research Council 1042231National Health and Medical Research Council 513781
6 · The paper itself

Abstract

backgroundThere are scant data relating to prognostic biomarkers for chronic kidney disease (CKD) complicating type 1 diabetes. The aim of this study was to assess the performance of the plasma protein biomarker-based PromarkerD test developed and validated for predicting renal decline in type 2 diabetes in the context of type 1 diabetes.

methodsThe baseline PromarkerD test score was determined in 91 community-based individuals (mean age 46.2 years, 56.5% males) with confirmed type 1 diabetes recruited to the longitudinal observational Fremantle Diabetes Study Phase II. The performance of the PromarkerD test in predicting the risk of incident CKD (estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m

resultsThe area under the receiver operating characteristic curve was 0.93 (95% confidence interval 0.87-0.99) for the composite renal endpoint, indicating strong predictive accuracy. The positive and negative predictive values at moderate (10% to < 20%) and high (≥ 20%) risk PromarkerD cut-offs were 46.7-50.0% and ≥ 92.0%, respectively.

conclusionsThese preliminary data suggest that PromarkerD is at least as good a prognostic test for renal decline in type 1 as type 2 diabetes.

Indexed as

Chronic kidney diseasePredictionProtein biomarkersType 1 diabetes

Identifiers

PMID39385270
PMCPMC11466018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.